202 related articles for article (PubMed ID: 27049594)
1. Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
Nord J Psychiatry; 2016 Aug; 70(6):450-5. PubMed ID: 27049594
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
BMC Psychiatry; 2016 Dec; 16(1):441. PubMed ID: 27955666
[TBL] [Abstract][Full Text] [Related]
3. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland.
Ingimarsson O; MacCabe JH; Sigurdsson E
Nord J Psychiatry; 2018 Oct; 72(7):497-500. PubMed ID: 30348045
[TBL] [Abstract][Full Text] [Related]
4. Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
Nord J Psychiatry; 2017 Oct; 71(7):496-502. PubMed ID: 28632422
[TBL] [Abstract][Full Text] [Related]
5. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?
Constantine RJ; Andel R; McPherson M; Tandon R
Psychiatry Res; 2018 May; 263():238-244. PubMed ID: 29195836
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
8. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
[TBL] [Abstract][Full Text] [Related]
9. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.
Üçok A; Çıkrıkçılı U; Ergül C; Tabak Ö; Salaj A; Karabulut S; Correll CU
CNS Drugs; 2016 Oct; 30(10):997-1006. PubMed ID: 27356920
[TBL] [Abstract][Full Text] [Related]
10. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
[TBL] [Abstract][Full Text] [Related]
11. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.
Howes OD; Vergunst F; Gee S; McGuire P; Kapur S; Taylor D
Br J Psychiatry; 2012 Dec; 201(6):481-5. PubMed ID: 22955007
[TBL] [Abstract][Full Text] [Related]
12. Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia.
Trinczek E; Heinzel-Gutenbrunner M; Haberhausen M; Bachmann CJ
Pharmacopsychiatry; 2016 Nov; 49(6):254-259. PubMed ID: 27737473
[No Abstract] [Full Text] [Related]
13. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clozapine discontinuation in patients with schizophrenia.
Krivoy A; Malka L; Fischel T; Weizman A; Valevski A
Int Clin Psychopharmacol; 2011 Nov; 26(6):311-5. PubMed ID: 21849905
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
17. Effect of clozapine on polypharmacy.
Chong SA; Remington GJ; Bezchlibnyk-Butler KZ
Psychiatr Serv; 2000 Feb; 51(2):250-2. PubMed ID: 10655014
[TBL] [Abstract][Full Text] [Related]
18. Reasons for discontinuing clozapine: A cohort study of patients commencing treatment.
Legge SE; Hamshere M; Hayes RD; Downs J; O'Donovan MC; Owen MJ; Walters JTR; MacCabe JH
Schizophr Res; 2016 Jul; 174(1-3):113-119. PubMed ID: 27211516
[TBL] [Abstract][Full Text] [Related]
19. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
[TBL] [Abstract][Full Text] [Related]
20. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India.
Grover S; Hazari N; Chakrabarti S; Avasthi A
Psychiatry Res; 2015 Mar; 226(1):181-5. PubMed ID: 25619433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
